Post-COVID-19 Syndrome Clinical Trial
Official title:
Impact of Anti-Inflammatory and Anti-Fibrotic Drugs on Post-acute COVID-19 Pulmonary Fibrosis
In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.
This study is a prospective and retrospective cohort study in which post COVID-19 patients who are following up at post COVID-19 clinic are evaluated regarding presence and degree of Post COVID-19 Pulmonary Fibrosis (PCPF) in relation to anti-inflammatory and/or anti-fibrotic drugs. Adult patients who have COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and according to WHO severity classification are (Moderate, severe, or critical) and has received either: - Corticosteroids alone (≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge) - Group A. - Corticosteroids in combination with Colchicine (1 mg/day for ≥ 10 days) - Group B. - Corticosteroids in combination with Pirfenidone (267 mg TID for ≥ 14 days) - Group C. - Corticosteroids in combination with Colchicine and Pirfenidone (for ≥ 14 days) - Group D. Pulmonary function test: Spirometry: measurement of lung volumes and capacities (forced expiratory volume in first second FEV1, Forced Vital Capacity FVC, FEV1/FVC and FEF25/75) after 1 month and 3 months of the onset of symptoms. Radiological scoring: Baseline High resolution CT scan of the chest will be performed at baseline, 1 month and 3 months after onset of symptoms. Chest CT-Severity Scoring (Chest CT-SS) for assessing COVID-19 burden on the initial scan will be calculated. This score uses lung opacification as a surrogate for extension of the disease in the lungs. According to the anatomic structure, the 18 segments of both lungs were divided into 20 regions, in which the posterior apical segment of the left upper lobe was subdivided into apical and posterior segmental regions, whereas the anteromedial basal segment of the left lower lobe was subdivided into anterior and basal segmental regions. The lung opacities in all the 20 lung regions were subjectively evaluated on chest CT images using a system attributing score of 0, 1, and 2 if parenchymal opacification involved 0%, less than 50%, or equal to or more than 50% of each region, respectively. The CT-SS was defined as the sum of the individual scores in the 20 lung segment regions, which may range from 0 to 40 points ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06073002 -
Effects of a Home-Based Exercise Intervention in Subjects With Long COVID
|
N/A | |
Completed |
NCT05047952 -
Vortioxetine for Post-COVID-19 Condition
|
Phase 2 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT06091384 -
Inspiratory Muscle Strength Training in Post-Covid Syndrome
|
N/A | |
Not yet recruiting |
NCT06267300 -
Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial
|
Phase 3 | |
Recruiting |
NCT05986422 -
Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
|
Phase 2 | |
Not yet recruiting |
NCT05534997 -
Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT05638633 -
Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT05630040 -
VNS for Long-COVID-19
|
N/A | |
Recruiting |
NCT05841498 -
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome
|
N/A | |
Enrolling by invitation |
NCT05981872 -
EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19
|
N/A | |
Active, not recruiting |
NCT05543408 -
Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial"
|
N/A | |
Recruiting |
NCT05817032 -
Effect of Telerehabilitation Practice in Long COVID-19 Patients
|
N/A | |
Recruiting |
NCT05823896 -
imPROving Quality of LIFe In the Long COVID Patient
|
Phase 2 | |
Completed |
NCT05764070 -
Impact of Vagus Nerve Stimulation on Post-Aerobic Activity Recovery in Post SARS-CoV-2 Patients
|
N/A | |
Completed |
NCT05765591 -
Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome
|
N/A | |
Recruiting |
NCT05918965 -
Vagus Stimulation in Female Long COVID Patients.
|
N/A | |
Not yet recruiting |
NCT06231238 -
Balance Acceptance and Commitment Therapy for Long COVID
|
Phase 2 | |
Completed |
NCT06282627 -
The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients
|
||
Active, not recruiting |
NCT05753202 -
tDCS in Post-COVID Syndrome: Comparison of Two Targets
|
N/A |